2Ward MM.Rheumatoid arthritis:Guidelines for the management of RA:breadth versus depth [ J ] .Nat Rev Rheumatol,2009,5 ( 6 ) :302-303.
3Katchamart W, Trudean J,Phumethum V, et al.Efficacy and toxicity of methotrexate ( MTX ) monotherapy versus MTX combination therapy with non-biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis:a systematic review and meta-analysis Ann Rheum Dis,2009,68 ( 7 ) :1105-1112.
4Bongartz T, Sutton AJ,Sweeting MJ,et al.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies:systematic review and meta-analysis of rare harmful effects in randomized controlled trial [ J ] .JAMA,2006,295 ( 19 ) :2275-2285.
9Burton W,Morrison A,Maclean R,et al.Systematic review of studies of productivity loss due to rheumatoid arthritis[J].Occup Med(Lond),2006,56(1):18-27.
10Saag KG,Teng GG,Patkar NM.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis[J].Arthritis Rheum,2008,59(6):762-784.
10Xiao Y, Shi M, Qiu Q, et al. Piperlongurnine suppresses dendritic cell maturation by reducing production of reactive oxygen species and has therapeutic potential for rheumatoid arthritis[J]. Jlmmunol, 2016, 196 (12) :4925-4934.
